248 related articles for article (PubMed ID: 37522238)
1. Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
Kim MM; Prasad M; Burton Y; Kolseth CM; Zhao Y; Chandrashekar P; Nazer B; Masri A
J Am Heart Assoc; 2023 Aug; 12(15):e029705. PubMed ID: 37522238
[TBL] [Abstract][Full Text] [Related]
2. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
Lau ATC; DiDomenico RJ; Kim K
Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
[TBL] [Abstract][Full Text] [Related]
4. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
Garcia-Pavia P; Sultan MB; Gundapaneni B; Sekijima Y; Perfetto F; Hanna M; Witteles R
JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.
Takashio S; Morioka M; Ishii M; Morikawa K; Hirakawa K; Hanatani S; Oike F; Usuku H; Kidoh M; Oda S; Yamamoto E; Matsushita K; Ueda M; Tsujita K
ESC Heart Fail; 2023 Aug; 10(4):2319-2329. PubMed ID: 37073415
[TBL] [Abstract][Full Text] [Related]
7. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
Davies DR; Redfield MM; Scott CG; Minamisawa M; Grogan M; Dispenzieri A; Chareonthaitawee P; Shah AM; Shah SJ; Wehbe RM; Solomon SD; Reddy YNV; Borlaug BA; AbouEzzeddine OF
JAMA Cardiol; 2022 Oct; 7(10):1036-1044. PubMed ID: 36069809
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
[TBL] [Abstract][Full Text] [Related]
10. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
11. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
12. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
[TBL] [Abstract][Full Text] [Related]
13. Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.
Wu YA; Yu AL; Cheng MF; Lin LC; Lee MJ; Chou CH; Shun CT; Hsueh HW; Juang JJ; Tseng PH; Lin SP; Su MY; Chao CC; Hsieh ST; Tsai CH; Lin YH
Ther Adv Chronic Dis; 2024; 15():20406223231222828. PubMed ID: 38223905
[TBL] [Abstract][Full Text] [Related]
14. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
[TBL] [Abstract][Full Text] [Related]
15. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.
Dobner S; Bernhard B; Asatryan B; Windecker S; Stortecky S; Pilgrim T; Gräni C; Hunziker L
ESC Heart Fail; 2023 Feb; 10(1):397-404. PubMed ID: 36259276
[TBL] [Abstract][Full Text] [Related]
17. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
[TBL] [Abstract][Full Text] [Related]
18. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
19. Amyloid Transthyretin Cardiomyopathy in Elderly Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
Dobner S; Pilgrim T; Hagemeyer D; Heg D; Lanz J; Reusser N; Gräni C; Afshar-Oromieh A; Rominger A; Langhammer B; Reineke D; Windecker S; Stortecky S
J Am Heart Assoc; 2023 Aug; 12(16):e030271. PubMed ID: 37581394
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
Grzybowski J; Podolec P; Holcman K; Gawor-Prokopczyk M; Jankowska E; Kostkiewicz M; Dąbrowska-Kugacka A; Lipowska M; Mazurkiewicz Ł; Rajtar-Salwa R; Rubiś P; Straburzyńska-Migaj E; Szczygieł J; Mitkowski P
Kardiol Pol; 2023; 81(11):1167-1185. PubMed ID: 37768101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
